Details about COVID-19, monkeypox, and the flu vaccine
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers
Trial ID or NCT#
Status
NOT RECRUITING
Purpose
The purpose of the study is to determine whether standardized implementation of a scripted template for discussing important issues that arise near the end of life improves the care of those who have advanced cancer.
Official Title
A Randomized, Controlled Trial Examining the Use of The "Serious Illness Conversation Guide" (SICG) in Patients With Advanced Gastro-Intestinal Cancers
Eligibility Criteria
- - Patients with metastatic colorectal cancer whose tumor has progressed on both FOLFOX and FOLFIRI. - Exception: Patients with metastatic colorectal cancer whose tumors demonstrate a BRAF V600E mutation may be enrolled regardless of prior chemotherapy. - Exception: Patients whose tumors are MSI-H must have experience progression through immunotherapy in addition to the therapies mentioned above. - Patients with metastatic pancreatic adenocarcinoma. - Patients with metastatic gastric or esophageal cancer whose tumor has progressed through first-line chemotherapy of any type. - Patients with metastatic cholangiocarcinoma whose tumor has progressed through first-line chemotherapy of any type. - Patients with metastatic hepatocellular carcinoma whose tumor has progressed through PD1 blockade. - Patients with metastatic high-grade neuroendocrine tumor. - A patient with a metastatic GIST that has progressed through first-line tyrosine kinase inhibitor. - Expected life expectancy of at least one month
- - Any patient not meeting the above criteria - Non-English speaking patients
Investigator(s)
Contact us to find out if this trial is right for you.
CONTACT
Daniel Holguin
(650) 736-3379
View on ClinicalTrials.gov
About this Clinical Trial
Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers
Your Message Will Go To
Daniel Holguin6507363379